WO2010003420A3 - Traitement du psoriasis et de maladies apparentées par modulation de miarn - Google Patents

Traitement du psoriasis et de maladies apparentées par modulation de miarn Download PDF

Info

Publication number
WO2010003420A3
WO2010003420A3 PCT/DK2009/050131 DK2009050131W WO2010003420A3 WO 2010003420 A3 WO2010003420 A3 WO 2010003420A3 DK 2009050131 W DK2009050131 W DK 2009050131W WO 2010003420 A3 WO2010003420 A3 WO 2010003420A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
treatment
related diseases
modulation
mirna
Prior art date
Application number
PCT/DK2009/050131
Other languages
English (en)
Other versions
WO2010003420A2 (fr
Inventor
John Robert Zibert
Lone Skov
Original Assignee
Gentofte Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentofte Hospital filed Critical Gentofte Hospital
Publication of WO2010003420A2 publication Critical patent/WO2010003420A2/fr
Publication of WO2010003420A3 publication Critical patent/WO2010003420A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'identification d'un profil de miARN dérégulés en cas de psoriasis et la modulation de ces espèces de miARN dérégulés pour le traitement du psoriasis et d'autres maladies apparentées. L'invention concerne également l'utilisation d'acides nucléiques 5 inhibiteurs, tels que des oligonucléotides antisens chimiquement modifiés, comme produits pharmaceutiques, par exemple pour le traitement du psoriasis et d'autres maladies apparentées.
PCT/DK2009/050131 2008-06-17 2009-06-17 Traitement du psoriasis et de maladies apparentées par modulation de miarn WO2010003420A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13227508P 2008-06-17 2008-06-17
US61/132,275 2008-06-17
DKPA200800845 2008-06-17
DKPA200800845 2008-06-17
DKPA200970002 2009-04-20
DKPA200970002 2009-04-20

Publications (2)

Publication Number Publication Date
WO2010003420A2 WO2010003420A2 (fr) 2010-01-14
WO2010003420A3 true WO2010003420A3 (fr) 2010-08-19

Family

ID=41011929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2009/050131 WO2010003420A2 (fr) 2008-06-17 2009-06-17 Traitement du psoriasis et de maladies apparentées par modulation de miarn

Country Status (1)

Country Link
WO (1) WO2010003420A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6997142B2 (ja) 2018-07-24 2022-02-03 チャン グァン メモリアル ホスピタル，カオシュン 乾癬性関節炎の診断及び治療

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008338530A1 (en) 2007-12-14 2009-06-25 Minitube Of America, Inc. Gender-specific separation of sperm cells and embryos
US20110190372A1 (en) * 2009-08-07 2011-08-04 New York University Compositions and methods for treating inflammatory disorders
WO2011032034A2 (fr) 2009-09-10 2011-03-17 University Of Idaho Nucléotides et oligonucléotides à conformation restreinte à fonctionnalité nucléobase pour cibler des acides nucléiques
CA2801342A1 (fr) 2010-06-04 2011-12-08 Eric N. Olson Regulation du metabolisme par mir-378
EP2668288B1 (fr) * 2011-01-28 2016-01-20 Comprehensive Biomarker Center GmbH Ensembles de miarn complexes en tant que nouveaux biomarqueurs pour des maladies pulmonaires
AR088140A1 (es) 2011-07-19 2014-05-14 Univ Idaho Sonda y metodo para direccionar acidos nucleicos
WO2013155371A1 (fr) * 2012-04-12 2013-10-17 Cornell University Microarn-31 comme agent diagnostique, pronostique et thérapeutique du cancer
CN111956632B (zh) * 2020-09-27 2022-10-18 上海市同仁医院 一种抗肿瘤的组合物及其应用
WO2024124315A1 (fr) * 2022-12-16 2024-06-20 Mirscience Therapeutics Servicos De Pesquisa E Desenvolvimento Ltda. Analogues oligonucléotidiques antisens de mir-29 et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
WO2006047454A2 (fr) * 2004-10-21 2006-05-04 Rutgers, The State University Of New Jersey Optimisation rationnelle des sondes utilisees pour la detection des micro arn
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2007095387A2 (fr) * 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions et procédés permettant l'inhibition de silençage de gènes par l'interférence arn

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (fr) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
WO2006047454A2 (fr) * 2004-10-21 2006-05-04 Rutgers, The State University Of New Jersey Optimisation rationnelle des sondes utilisees pour la detection des micro arn
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
WO2007095387A2 (fr) * 2006-02-17 2007-08-23 Dharmacon, Inc. Compositions et procédés permettant l'inhibition de silençage de gènes par l'interférence arn

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 9 October 2007 (2007-10-09), "Sequence 40 from Patent WO2007073737.", XP002544438, retrieved from EBI accession no. EMBL:CS692048 Database accession no. CS692048 *
DATABASE Geneseq [online] 13 December 2007 (2007-12-13), "Human miRNA targeting inhibitor, SEQ ID 680.", XP002544433, retrieved from EBI accession no. GSN:ALK31237 Database accession no. ALK31237 *
DATABASE Geneseq [online] 13 December 2007 (2007-12-13), "Human miRNA targeting inhibitor, SEQ ID 748.", XP002544434, retrieved from EBI accession no. GSN:ALK31305 Database accession no. ALK31305 *
DATABASE Geneseq [online] 14 June 2007 (2007-06-14), "LNA probe rno-miR129*/LNA used to detect conserved vertebrate miRNAs.", XP002544437, retrieved from EBI accession no. GSN:AFO07994 Database accession no. AFO07994 *
DATABASE Geneseq [online] 21 September 2006 (2006-09-21), "Mouse probe for miRNA #80.", XP002544439, retrieved from EBI accession no. GSN:AEJ22146 Database accession no. AEJ22146 *
DATABASE Geneseq [online] 21 September 2006 (2006-09-21), "Rat probe for miRNA #29.", XP002544440, retrieved from EBI accession no. GSN:AEJ22489 Database accession no. AEJ22489 *
DATABASE Geneseq [online] 29 June 2006 (2006-06-29), "micro RNA miRNA-detection probe 2346.", XP002544435, retrieved from EBI accession no. GSN:AEH32302 Database accession no. AEH32302 *
DATABASE Geneseq [online] 29 June 2006 (2006-06-29), "micro RNA miRNA-detection probe 2627.", XP002544436, retrieved from EBI accession no. GSN:AEH32583 Database accession no. AEH32583 *
DATABASE Geneseq [online] 5 May 2005 (2005-05-05), "Antisense oligonucleotide targeting a human miRNA, ISIS344342.", XP002544432, retrieved from EBI accession no. GSN:ADX04670 Database accession no. ADX04670 *
KIM JOHN ET AL: "Identification of many microRNAs that copurify with polyribosomes in mammalian neurons.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 6 JAN 2004, vol. 101, no. 1, 6 January 2004 (2004-01-06), pages 360 - 365, XP002544430, ISSN: 0027-8424 *
SONKOLY E ET AL: "MicroRNAs: novel regulators in skin inflammation", CLINICAL AND EXPERIMENTAL DERMATOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 33, no. 3, 1 May 2008 (2008-05-01), pages 312 - 315, XP002511185, ISSN: 0307-6938 *
SONKOLY ENIKÖ ET AL: "MicroRNAs: novel regulators involved in the pathogenesis of Psoriasis?", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, vol. 2, no. 7, 1 July 2007 (2007-07-01), pages e610 - 1, XP002511184, ISSN: 1932-6203 *
TILI ESMERINA ET AL: "Expression and function of micro-RNAs in immune cells during normal or disease state.", INTERNATIONAL JOURNAL OF MEDICAL SCIENCES 2008, vol. 5, no. 2, 2008, pages 73 - 79, XP002544431, ISSN: 1449-1907 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6997142B2 (ja) 2018-07-24 2022-02-03 チャン グァン メモリアル ホスピタル，カオシュン 乾癬性関節炎の診断及び治療

Also Published As

Publication number Publication date
WO2010003420A2 (fr) 2010-01-14

Similar Documents

Publication Publication Date Title
WO2010003420A3 (fr) Traitement du psoriasis et de maladies apparentées par modulation de miarn
WO2010141511A3 (fr) Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser
WO2008104978A3 (fr) Nouvelles structures d'arnsi
EP4279610A3 (fr) Purification d'acide ribonucléique
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
IL243178B (en) Double-stranded ribonucleic acids (dsrna) to inhibit the expression of transthyretin (ttr), pharmaceutical preparations containing them, and their use in the treatment of disorders resulting from transthyretin expression
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
EP2274442A4 (fr) Séquences consensus de protéines du virus chikungunya, molécules d acide nucléique codant pour celles-ci, et compositions et procédés d utilisation de celles-ci
WO2011005761A8 (fr) Nouveaux précurseurs d'acide nucléique et leurs méthodes d'utilisation
WO2011085066A3 (fr) Traitement de maladies associées à un gène de développement pancréatique par inhibition du produit de la transcription anti-sens naturel en un gène de développement pancréatique
WO2011138328A3 (fr) Utilisation de molécules inhibitrices pour le traitement d'une hypertension artérielle pulmonaire
WO2011022357A3 (fr) Enzymes de clivage de snare à action rapide
WO2010017436A3 (fr) Modulation de l’expression du gène de réponse primaire de différenciation de cellules myéloïdes 88 (myd88) par des oligonucléotides antisens
WO2011017516A3 (fr) Traitement de maladies liées à un gène de l'insuline (ins) par inhibition du transcrit antisens naturel d'un gène de l'insuline (ins)
WO2010017154A3 (fr) Modulation de l'expression de récepteur de type toll 3 par des oligonucléotides antisens
WO2014111876A3 (fr) Modulation de la mitophagie et son utilisation
WO2015032800A3 (fr) Compositions et procédés d'induction de la sénescence dans des cellules cancéreuses
WO2011021177A3 (fr) Compositions et procédés de pronostic et de traitement du cancer de la prostate
WO2015007871A3 (fr) Micro-arn et maladie inflammatoire à médiation auto-immune
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2009071680A3 (fr) Composés d'antagonistes d'arn utiles pour moduler mcl-1
WO2009147658A3 (fr) Compositions et procédés pour le diagnostic, le pronostic et le traitement d'un mésothéliome
WO2011045573A3 (fr) Antigènes staphylococciques
EP2046394A4 (fr) Utilisation de séquences d'acide nucléique pour le traitement de maladies neurologiques et psychiatriques, vecteurs et compositions
WO2011054939A3 (fr) Compositions et procédés pour inhiber l'expression de gènes kif10

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09776221

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010001467

Country of ref document: CL

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09776221

Country of ref document: EP

Kind code of ref document: A2